Aug 11, 2018 - Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday
Aug 09, 2018 - For the month Ending July 30, 2018 Performance Overview Domestic moat companies, as represented by the Morningstar Wide Moat Focus IndexSM (MWMFTR, or U.S. Moat Index), once again posted strong result
Aug 07, 2018 -
Aug 07, 2018 - Names on the move ahead of the open.
Jul 25, 2018 - GlaxoSmithKline plc (NYSE:GSK) Q2 2018 Results Earnings Conference Call July 25, 2018, 9:15 AM ET Executives Emma Walmsley - Chief Executive Officer Luke Miels - President, Global Pharmaceuticals Simo
Jul 25, 2018 - The following slide deck was published by GlaxoSmithKline in conjunction with their 2018 Q2 earnings call.
Jul 25, 2018 - GlaxoSmithKline is taking a deeper dive into genetics, with a large investment in Mountain View, California-based genetic profiling company 23andMe and a new approach to research and development.
The London-based pharmaceutical giant, which has operations in Research Triangle Park, entered into a 4-year, $300 million collaboration with 23andMe that will focus on new medicines and potential cures for diseases – using human genetics as the basis for discovery.
The $300 million represents an equity…
Jul 25, 2018 - GlaxoSmithKline is taking a deeper dive into genetics, with a large investment in a genetic profiling company and a new approach to research and development.
The London-based pharmaceutical giant has entered into a four-year, $300 million collaboration with 23andMe that will focus on new medicines and potential cures for diseases – using human genetics as the basis for discovery.
The $300 million represents an equity investment GSK is making in 23andMe.
Based in Mountain View, Calif., 23andMe…
Jul 25, 2018 - GlaxoSmithKline obtains positive results in treating patients with HIV from two duplicate phase 3 studies. The two-drug HIV regimen from GlaxoSmithKline's dolutegravir and lamivudine achieved closely
Jul 25, 2018 - Merck's (MRK) key cancer drug Keytruda succeeds as a monotherapy in phase III program. It is being evaluated for the first-line treatment of patients with advanced head and neck cancer.